Nanotechnology firm Liquidia partners with PATH on new pneumonia vaccine
December 13, 2011
Research Triangle Park-based Liquidia is working with PATH to conduct preclinical studies on a “next generation” pneumococcal vaccine that could be more effective than existing vaccines and more efficient to produce. Financial terms of the partnership were not disclosed. But it’s not the first time the two entities have worked together. Liquidia has also partnered with PATH’s Malaria Vaccine Initiative to develop a new malaria vaccine.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.